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Abstract
The objective of the study was to identify the mechanism of action for a radiation miti-
gator of the gastrointestinal (GI) acute radiation syndrome (ARS), identified in an unbi-
ased high-throughput screen. We used mice irradiated with a lethal dose of radiation
and treated with daily injections of the radiation mitigator 1-[(4-nitrophenyl)sulfonyl]-
4-phenylpiperazine to study its effects on key pathways involved in intestinal stem cell
(ISC) maintenance. RNASeq, quantitative reverse transcriptase-polymerase chain reac-
tion, and immunohistochemistry were performed to identify pathways engaged after
drug treatment. Target validation was performed with competition assays, reporter
cells, and in silico docking. 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine activates
Hedgehog signaling by binding to the transmembrane domain of Smoothened, thereby
expanding the ISC pool, increasing the number of regenerating crypts and preventing
the GI-ARS. We conclude that Smoothened is a target for radiation mitigation in the
small intestine that could be explored for use in radiation accidents as well as to miti-
gate normal tissue toxicity during and after radiotherapy of the abdomen.
K E YWORD S
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1 | INTRODUCTION
Exposure to even moderate doses of radiation expected during nuclear
accidents, after deployment of “dirty bombs” or attacks with nuclear
weapons has severe effects on normal tissue compartments that will
lead to the development of a set of symptoms summarized as acute
radiation syndrome (ARS).1 In particular, damage to the hematopoietic
system and the gut after total body radiation (TBI) exposure is often
lethal and difficult to control even under optimal supportive care.2 The
characteristic feature of the gastrointestinal ARS (GI-ARS) is the rapid
loss of the integrity of the epithelial layer lining the intestines. This
results in poor resorption of nutrients and fluids in the gut and loss of
the intestine's barrier function. Seven to 10 days after radiation expo-
sure, exposed individuals experience dehydration, sepsis, and bleeding,
cumulatively leading to death. Previous studies established that in
mouse models of GI-ARS the number of regenerating crypts per cir-
cumference at 5 days after irradiation is inversely correlated with the
radiation dose and determines if the animals recover.3,4
Generally, radiation-induced death of differentiated cells and loss
of tissue specific stem cells are the underlying mechanisms forSara Duhachek-Muggy and Kruttika Bhat contributed equally to the study.
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radiation-induced loss of tissue function. In the small intestines,
finger-like structures called villi form a large epithelial surface respon-
sible for the absorption of nutrients. The epithelial cells of these villi
originate from intestinal stem cells (ISCs) found at the base of crypt-
like structures surrounding the villi.5 Rapidly proliferating transiently
amplifying cells produce differentiated progeny that migrate toward
the tip of the villi in a conveyer belt-like fashion where they shed into
the intestinal lumen and die. In response to irradiation the villi are lost
but depending on the radiation dose, the tissue is restored over time
by the surviving ISCs able to initiate regenerating crypts.4
In the event of an exposure to radiation during nuclear accidents, or
by nuclear explosive devices and “dirty bombs,” treatments are needed to
mitigate radiation damage to the hematopoietic system and the gut, in
order to prevent ARS.6,7 Mass-casualty scenarios come with multiple
logistic challenges that make successful distribution of drugs to a large
number of victims within the first 24 hours after an incident unlikely.8-10
Currently, there are very fewdrugs known tomitigate the effects of radia-
tion when applied 24 hours after radiation exposure or later.7 A recent
high-throughput screen performed by the UCLA Center for Medical
Countermeasures against Radiation identified compounds with radiation
mitigator properties to the hematopoietic system and the gut.11,12 Among
these compounds, 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine
(compound #5; Figure 1A) most efficiently mitigated hematopoietic and
GI-ARS. However, the underlyingmechanisms of action were not investi-
gated12 and are addressed in our present study.
Here, we hypothesized that drugs that successfully mitigate radia-
tion damage in the small intestine impact ISC survival and/or expan-
sion. We report that compound #5 modulates Hedgehog signaling in
the crypts of the small intestines by binding to Smoothened and
thereby leading to ISC compartment expansion, improved intestinal
recovery, and survival of lethally irradiated animals.
2 | MATERIALS AND METHODS
2.1 | Animals
C3Hf/Sed/Kam were originally obtained from the MD Anderson Can-
cer Center. All mice were rederived, bred, and maintained in a
pathogen-free environment in the American Association of Laboratory
Animal Care-accredited Animal Facilities of Department of Radiation
Oncology, University of California (Los Angeles, California) in accor-
dance to all local and national guidelines for the care of animals.
2.2 | Irradiation
Twelve-week-old C3Hf/Sed/Kam mice were irradiated in groups of
five animals using an experimental x-ray irradiator (Gulmay Medical
Inc, Atlanta, Georgia) at a dose rate of 2.8159 Gy/minute for the time
required to apply a prescribed dose. Radiation was administered
between 11:30 a.m. and 1:30 p.m. to minimize variation of circadian
effects on radiation responses.13 Control animals were sham-
irradiated. The x-ray beam was operated at 300 kV and hardened
using a 4 mm Be, a 3 mm Al, and a 1.5 mm Cu filter. For total abdomi-
nal irradiation (TAI) the rest of the body was shielded with 10 mm lead
blocks.
2.3 | In vivo drug administration
Twenty-four hours after irradiation mice received a single subcutane-
ous injection of 5 mg/kg of 1-[(4-nitrophenyl)sulfonyl]-
4-phenylpiperazine (compound #5, Vitascreen, Champaign, Illinois)
dissolved in 15 μL DMSO (Dimethylsulfoxide) and then suspended in
1 mL of 1% Cremophor EL. Control animals received DMSO/
Cremophor EL only. For survival studies mice received five daily doses
of the drug spaced by 24-hour intervals. To assess toxicity, the mice
were weighed daily.
2.4 | Microcolony stem cell assay
Mice were irradiated with 16 Gy TBI. Twenty-four hours after irradia-
tion, the animals were treated with compound #5, as described above,
and were treated daily until tissue harvesting. The technique of With-
ers and Elkind4 was used to assay the survival of intestinal crypts
96 hour following TBI. Briefly, the entire small intestine was excised
and divided into duodenum, jejunum, or ileum using a ratio of total
small intestine length of 1:3:2, respectively. The central 2.5 cm of
duodenum and jejunum were fixed in neutral buffered formalin, and
4-6 segments (~0.5 cm in length) were taken from the fixed regions of
each mouse and embedded in paraffin. Tissue sections were cut at a
thickness of 4 μm and stained with hematoxylin and eosin. The num-
bers of regenerating crypts containing at least 10 viable cells were
counted microscopically using ×20 magnification on a BZ-9000 micro-
scope (Keyence, Itasca, Illinois).
Significance statement
Exposure to lethal doses of ionizing radiation manifests in a
symptom complex that is summarized as acute radiation
syndrome (ARS) and the extent of radiation damage to the
hematopoietic and gastrointestinal (GI) systems codetermine
the acute survival of the exposed individual. So far, no per-
son who experienced a full-scale GI-ARS has ever survived.
This creates a—so far—mostly unmet need to develop coun-
termeasures that mitigate the effects of lethal radiation
doses when given after radiation exposure. This study pre-
sents that a piperazine compound prevents GI-ARS in mice
when given 24 hours after a lethal dose of radiation and
uncovers the underlying mechanism of action, thus provid-
ing a basis for a future rational development of effective
radiation mitigators.
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2.5 | Quantitative reverse transcription PCR
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
was performed in the QuantStudio 3 Real-Time PCR System (Applied Bio-
systems, Carlsbad, California) using the PowerUp SYBRGreenMasterMix
(Applied Biosystems). Ct for each gene was determined and ΔΔCt was
calculated relative to the designated reference sample. Gene expression
values were then set equal to 2−ΔΔCt as described by the manufacturer of
the kit (Applied Biosystems). PCR primers were synthesized by Invitrogen
and the sequences are shown in Table S1. Hypoxanthine Phos-
phoribosyltransferase, ribosomal Protein Lateral Stalk Subunit P0, and
peptidyl-Prolyl-Cis-Trans Isomerase Awere used as housekeeping genes.
F IGURE 1 Compound #5 significantly improves survival and mitigates weight loss after a lethal dose of radiation. A, Structure of
1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine/compound #5. B, Female 12-week-old C3H mice were abdominally irradiated with 20 Gy (n = 13
per group or n = 26 total) or 20.5 Gy (n = 15 per group or n = 30 total). Twenty-four hours later, the animals were treated with compound #5
(5 mg/kg) or Cremophor/DMSO subcutaneously, followed by another four daily treatments. Animals treated with 20 Gy did not reach median
survival. By day 11, after exposure to irradiation 80% of the mice succumb to a single dose of 20.5 Gy. However, only five daily treatments with
compound #5, beginning 24 hours after irradiation exposure, significantly improved survival with only 31% of the mice succumbing by day
11 postirradiation (P = .0056, log-rank [Mantel-Cox]) test. C and D, Weights on day 10 after exposure to either 20 Gy (C) or 20.5 Gy (D) total
abdominal irradiation were normalized to the animals starting weights and shown as a percent difference from the Cremophor/DMSO-treated
animals. Compound #5 significantly improved weight loss in animals exposed to 20 Gy (P = .0206, Student's t test) and trended similarly, but not
significantly, in animals treated with 20.5 Gy (P = .0625, Student's t test). E-G, Female, 12-week-old C3H mice received 16 Gy of total body
irradiation, and beginning 24 hours after irradiation, were administered subcutaneous injections of compound #5 (5 mg/kg) or Cremophor/DMSO
daily. Ninety-six hours after irradiation, the duodenums were removed, fixed, embedded in paraffin, and thin cross-sections were stained with
H&E. E and F, The number of regenerating crypts (E, F; white arrows, bottom panels) present in at least five cross-sections per mouse were
counted at high magnification (×20; E, F; bottom panels). Treatment with compound #5 resulted in a significant increase in the average number of
regenerating crypts per circumference after exposure to a lethal dose (16 Gy) of total body irradiation (G, n = 8 mice per group, P = .0158,
unpaired, two-tailed, Student's t test). Scale bars in (E/F) upper images 500 μm, lower images 100 μM
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2.6 | RNASeq
Four hours after drug treatment, RNA was extracted from the proxi-
mal portion of the duodenum using Trizol. RNASeq analysis was per-
formed by Novogene (Chula Vista, California). Quality and integrity of
total RNA was controlled on a Bioanalyzer (Agilent Technologies,
Waldbronn, Germany). The RNA sequencing library was generated
using NEBNext Ultra RNA Library Prep Kit (New England Biolabs, Ips-
wich, Massachusetts). The library concentration was quantified using
a Qubit 3.0 fluorometer (Life Technologies, Carlsbad, California), and
then diluted to 1 ng/μL. Insert size was checked (2100 Bioanalyzer,
Agilent Technologies; Waldbronn, Germany) and quantified by qPCR
(library molarity >2 nM). The library was sequenced (Illumina
NovaSeq6000) with an average of 50 M reads per sample.
Downstream analysis was performed using STAR, HTseq, and
Cufflink. Alignments were parsed using Tophat and differential expres-
sions were determined through DESeq2. Reference genome and gene
model annotation files were downloaded from genome website
browser (University of California, Santa Cruz) directly. Indexes of the
reference genome were built using spliced transcripts alignment to a
reference (STAR) and paired-end clean reads were aligned to the refer-
ence genome, using STAR (v2.5). HTSeq v0.6.1 was used to count the
read numbers mapped of each gene. The Fragments per Kilobase of
Transcript per Million Mapped Reads of each gene was calculated
based on the length of the gene and reads count mapped to this gene.
Differential expression analysis between was performed using
the DESeq2 R package (2_1.6.3). The resulting P-values were adjusted
using the Benjamini and Hochberg's approach for controlling the false
discovery rate. Genes with an adjusted P-value of <.05 were assigned
as differentially expressed. Gene set enrichment analysis of differen-
tially expressed genes was performed using the Broad Institute's
Molecular Signature Database (MSigDB).14,15 Gene sets with
corrected P-values less than .05 were considered significantly
enriched by differential expressed genes.
2.7 | Immunohistochemistry
Cross-sections of the small intestines were fixed in formalin, embed-
ded in paraffin, and 4 μm sections were stained for Ki67, β-catenin,
and the intracellular domain of Notch (Notch-ICD; Translational
Pathology Core Laboratory at UCLA). Briefly, slides were placed in
xylenes to remove paraffin, then a series of ethanol, washed in tap
water, and incubated in 3% hydrogen peroxide/methanol for
10 minutes. After a wash in distilled water, the slides were incubated
for 25 minutes in citrate buffer, pH 6 at 95C. The slides rinsed in
phosphate buffered saline containing 0.05% tween-20 (PBST), and
then incubated with a rabbit anti-mouse Ki67 antibody (Cell Signaling,
Danvers, MA, #12202; 1:200) or rabbit anti-β-catenin antibody (Cell
Signaling, #9562; 1:50) at RT for 1 hour and with a rabbit anti-
Notch1-ICD antibody (Abcam, #ab8925, 1:50, Cambridge, UK) over-
night at 4C. The slides were rinsed with PBST, and were incubated
with secondary polymer at RT for 30 minutes; the polymers used
were Dako EnVision + System-HRP Labeled Polymer anti-rabbit
(Dako, Carpinteria, CA, #K4003) for Ki67 or MACH3 rabbit HRP poly-
mer (Biocare Medical, Concord, California) for β-catenin. Slides were
rinsed with PBST and incubated with 3,30-diaminobenzidine, washed
in tap water, counterstained with Harris' hematoxylin, dehydrated in
ethanol, and mounted with media. Slides were visualized using a BZ-
9000 fluorescence microscope (Keyence, Osaka, Japan) at ×60 magni-
fication. The numbers of Ki67+ nuclei were counted per region of
interest for a total of 8-10 images per animal. Slides were stained for
YAP (Yes-associated Protein)/TAZ using a rabbit anti-human antibody
(Cell Signaling, #8418; 1:200) and secondary anti-rabbit FITC-
conjugated secondary antibody, the nuclei counterstained with DAPI
and analyzed using a confocal microscope.
2.8 | Enteroid isolation
Intestinal enteroids were prepared as previously described.16 Briefly,
mice were sacrificed and the small intestine was harvested, flushed
with phosphate buffered saline (PBS) and opened longitudinally. The
villi were then scraped off using an ice-cold glass slide, washed with
PBS (×3), chopped into small segments, dropped in a 50 mL tube con-
taining 20 mL of ice-cold PBS with Pen/Strep and washed by
pipetting up and down. After segments were allowed to settle by
gravity, the supernatant was discarded and the procedure was
repeated approximately 15-20 more times until the solution was clear.
The intestinal segments were resuspended in PBS with 5 mM EDTA
and rocked at 20 rpm for 15 minutes at room temperature. The seg-
ments were then allowed to settle by gravity and the pellets
resuspended in 10 mL of ice-cold PBS with 0.1% BSA, pipetted three
times and allowed to settle. The supernatant was collected, passed
through a 70 μm filter into a 50 mL tube and saved as fraction 1 (F1).
The procedure was repeated to obtain fractions 2-4 (F2-F4). The frac-
tions were centrifuged at 290g for 5 minutes at 4C. The supernatant
was discarded and the pellet was resuspended in 10 mL of PBS
+ 0.1% BSA. The suspension was centrifuged at 200g at 4C. The pel-
let was resuspended in 5 mL of Dulbecco's modified Eagle's medium
(DMEM)/F12 medium (Gibco). The fractions containing the most
crypts were pelleted and resuspended in 50% complete IntestiCult
Organoid Growth Medium (STEMCELL Technologies, Vancouver, Brit-
ish Columbia, Canada) and 50% Matrigel (Corning, Corning,
New York). All experiments were performed on cultured crypts on
passage #2-7. For passaging, growth media was removed and cold
PBS with 5 mM EDTA was added to each well. The Matrigel was
mechanically disrupted using a P1000 pipette tip and the solution was
rocked at 20 rpm at RT for 15 minutes. The disrupted crypts were pel-
leted by centrifugation at 290g for 5 minutes at 4C.
2.9 | Quantitative budding crypt assay
Budding crypt assays were conducted by plating 60 μL of crypt mix-
ture, containing 150 crypts (for wells treated with radiation) or
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50 crypts (for nonirradiated controls), into each well of a prewarmed
96-well plate. The Matrigel was allowed to solidify and then complete
IntestiCult Organoid Growth Medium was slowly added to cover the
embedded crypts. The plate was incubated at 37C overnight and irra-
diated the following day with 0 Gy or 3 Gy. Compound #5 was added
3 hours or 24 hours later and the media was changed daily for
6-8 days. The number of enteroids with budding crypts was deter-
mined once the crypts reached maturity.
2.10 | R-Spondin1 replacement assay
Intestinal enteroids from 6 to 8-week-old female C3H mice were pre-
pared as described above. Enteroids were dissociated into crypts and
resuspended in 1:1 Matrigel:enteroid growth medium (advanced
DMEM/F12 supplemented with 1% penicillin/streptomycin, 10 mM
HEPES, 1% GlutaMAX [all from Gibco], 1× N-2MAX [R&D Systems
Minneapolis, MN], 1× SM1 [STEMCELL Technologies], 1 μM
N-acetylcysteine [Sigma], 50 ng/mL EGF, 100 ng/mL Noggin, 10 μM
Y-27632 [all from STEMCELL Technologies]) in the presence or absence
of 1 μg/mL R-Spondin1 (PeproTech, Westlake village, California). Crypts
were plated in a 96well plate in triplicates at the density of 50 crypts per
well for nonirradiated wells and 150 crypts irradiated wells. After the
Matrigel solidified, fresh enteroid growth media supplemented with
10 μM compound #5 or DMSO was added and the crypts were incu-
bated at 37C overnight. The following day, the plates were irradiated
with 0 Gy or 3 Gy. The media was replaced daily for 6 days after which
the number of budding crypts was determined.
2.11 | Smoothened binding assay
HEK293 cells were cultured in DMEM supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin under standard condi-
tions. Cells were transfected with a plasmid coding for mCherry-
tagged murine Smoothened protein (mCherry-Smoothened1-N-18
was a gift from Michael Davidson, Addgene plasmid #55134). For
binding studies cells were plated and treated with BODIPY-
cyclopamine (Biovision, Milpitas, California) at 5 nM for 2 hours in the
presence or absence of compound #5. After 2 hours, cells were
washed in PBS, fixed with paraformaldehyde and imaged using a fluo-
rescence microscope (BZ-9000) or analyzed by flow cytometry (LSR II,
Becton Dickinson, Franklin Lakes, NJ and FlowJo v10).
2.12 | Gli reporter luciferase assay
A Gli reporter luciferase assay was performed following the manufac-
turer's protocol. Briefly, Gli Reporter—NIH3T3 cells (catalog
no. 60409, BPS Bioscience, San Diego, California) were harvested and
seeded in a white clear bottom 96-well plate at a density of
25,000 cells per well in 100 μL of the growth medium. The cells were
incubated at 37C overnight in a CO2 incubator. The following day,
fresh media with compound #5 (0.1, 1, 10, and 100 μM) or Vis-
modegib (5 and 10 μM) were added. Cells were incubated for 2 hours
after which recombinant murine sonic hedgehog (mShh) protein
(1 μg/mL) was added to the positive control wells and the Vismodegib
wells. Cells were incubated for an additional 30 hours. The luciferase
assay was performed using the ONE-Step Luciferase Assay System
(catalog no. 60690, BPS Bioscience). Hundred microliters of the sub-
strate was added to each well and rocked at RT for 15 minutes. The
resulting luminescence was assessed using a plate reader (SpectraMax
M5, Molecular Devices, Sunnyvale, California) at room temperature.
2.13 | In silico docking experiments
Docking was performed using Autodock 4.2.17 The crystal structure of
human Smoothened in complex with TC114 (5V57) was downloaded
from the protein database (http://www.rcsb.org/pdb). The ligands were
removed in Chimera.18 The receptor data was imported into
AutoDockTools (vers 1.5.6, Scripps Institute), water was removed,
hydrogens were added and polar hydrogens merged. The ligand 3D
structure for 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine was down-
loaded from Chemspider (ID672004), converted using OpenBabel19
and entered into AutoDockTools. A grid box of 126 Å × 126 Å × 126 Å
with a gridcenter at −103.522, −112.608, 51.04, and grid point spacing
of 0.2 Å was generated to cover the known binding site for Smooth-
ened antagonists and agonists within the transmembrane domain of
Smoothened. Affinity maps of the present atoms and an electrostatic
map were calculated using AutoGrid. The protein structure was consid-
ered rigid and the ligand was considered to be flexible. Every docking
result was derived from 25 genetic algorithm runs, which terminated
after a maximum of 2.5 × 106 energy evaluations and a maximum of
2.7 × 104 generations with a population size of 150 and a rate of gene
mutation of 0.02 and a crossover rate of 0.8. The results were ranked
based on their predicted binding energy.
2.14 | Statistics
All analyses were performed in the GraphPad Prism software package.
Two-sided Student's t tests and a two-way analysis of variance for mul-
tiple comparisons were used. A log-rank test was used to determine a
P-value for the Kaplan-Meier survival curves in Figure 1. A P-value
equal to or smaller than .05 was considered statistically significant.
3 | RESULTS
3.1 | Compound #5 mitigates the effects of TAI
C3H mice were subjected to TAI of 20.5 Gy at the published LD70/10
for this mouse strain.20 A second set of animals were irradiated with a
dose of 20 Gy, an LD70/10. Twenty-four hours after irradiation, mice
were treated with daily subcutaneous injections of compound #5 at
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5 mg/kg, solubilized in DMSO/Cremophor, for five consecutive days.
Control animals were treated with radiation and DMSO/Cremophor
only. Median survival in animals treated with 20 Gy and Cremophor/
DMSO (n = 13) or 20 Gy and compound #5 (n = 13) was not reached.
Seventy percent (9/13) of the animals survived in the 20 Gy/
Cremophor/DMSO group and 77% (10/13) survived in the 20 Gy/
compound #5 group. The median survival of control mice treated with
20.5 Gy (n = 15) was 10 days, thus indicating death due to an GI-ARS
and confirming the very steep dose response curve for TAI.20 Only
2/15 animals were alive 30 days after irradiation with 20.5 Gy. Five
daily injections of compound #5 starting 24 hours after irradiation
resulted in 61% (8/13) of the animals surviving 30 days after being
exposed to 20.5 Gy (Figure 1B, P = .0056, log-rank test) and
prevented weight loss in animals irradiated with 20 Gy (Figure 1C,
P = .0206). The same trend was observed in animals treated with
20.5 Gy but did not meet the threshold for statistical significance
(Figure 1D, P = .0625).
3.2 | Compound #5 promotes crypt regeneration
and expands the stem cell compartment
Accidental radiation exposure will rarely be restricted to the abdomen
andMason et al demonstrated that at high radiation doses ISC survival in
mice is independent of the irradiation technique (TBI or TAI).20
Therefore, to test the effect of compound #5 on the survival of ISCs, ani-
mals were treated with 16 Gy TBI (LD50/10).
20 Twenty-four hours after
irradiation administration of compound #5 (5 mg/kg) in DMSO/
Cremophor, or DMSO/Cremophor only was started and administered
daily. Animals were euthanized 96 hours after irradiation and cross-
sections of the small intestines were analyzed for the appearance of reg-
enerating intestinal crypts (Figure 1E,F). In animals irradiated with 16 Gy,
followed 24 hours later by four daily treatments with compound #5, the
number of regenerating crypts4 at 96 hours after irradiation (72 hours
after first application of compound #5) increased twofold (P = .0158;
Figure 1G), suggesting an increased number of surviving or newly formed
ISCs in compound #5-treated animals. In the absence of irradiation,
treatment with compound #5 resulted also in a change in distribution of
the villi length, with a higher percentage of villi having a shorter length in
mice treated with compound #5. In Cremophor-treated animals, 46.3%
of villi were between 100 to 300 μm in length, whereas 24 hours after a
single dose of compound #5, 58.6% of the villi were in this size range
(not significant, Figure 2A,B,E). Irradiation with 16 Gy decreased the
number of villi longer than ~400 μm, and treatment with a single dose of
compound #5 (24 hours postirradiation) hadminimal effect on villi length
at 48 and 96 hours postirradiation and 24 and 72 hours after compound
#5 treatment (Figure 2C-E). In addition, treatment with compound #5
resulted in no change in the thickness of the submucosa (Figure 2F).
In agreement with the observed increase in the number of reg-
enerating crypts in the intestines of mice treated with compound #5,
F IGURE 2 Compound #5 does not significantly alter villi length or submucosa thickness in the small intestines of irradiated mice. Female
12-week-old C3H mice received 16 Gy of total body irradiation or sham irradiation and 24 hours later were administered a single dose of
compound #5 (5 mg/kg) or Cremophor/DMSO (crem) subcutaneously. A-D, Mice were sacrificed 24 hours, 48 hours, and 72 hours after
administering compound #5 and the small intestines were removed, fixed, and small cross-sections were stained with H&E. A scale bar for
(A)-(D) representing 100 μM is depicted in (D). E, The length of the villi lining the entire circumference was measured in at least five cross-
sections per mouse. The percent of villi with a certain length was plotted against the villi length to create a distribution of villi length for each
treatment group. At 24 and 72 hours after compound #5 treatment, there was a modest increase in the percentage of shorter villi (E, black filled
plots are the distributions of villi length for Cremophor-treated animals and the red lines represent compound #5 treated animals). F, The
submucosa thickness was measured in the tissue sections from mice at 24 hours after compound #5 or Cremophor treatment. There was no
significant effect on submucosa thickness after treatment with compound #5 (Student's t tests, P > .2 for all comparisons)
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we observed a significant increase in the number of proliferating
(Ki67-positive) cells within the crypt compartment of the small intes-
tines of mice irradiated with 16 Gy followed by treatment with com-
pound #5, 24 hours after irradiation (Figure 3C-E, P < .0001).
However, compound #5 did not affect the number of Ki67-positive
nuclei in unirradiated tissues (Figure 3A,B,E, P = .3612). In non-
irradiated animals, Ki67 staining was most prominent in the region of
transiently amplifying cells and—although weaker—also present in
crypt base columnar cells (CBC cells; Figure 3B).
To test the effect of compound #5 on the function of ISCs more
directly, we generated intestinal enteroids from the small intestines of
C3H mice and treated the enteroid cultures with a single dose of 3 Gy
in vitro, followed by addition of compound #5 either 3 hours or
24 hours postirradiation. The number of enteroids with budding crypts
was determined after 6 days. A significant increase in the number of
functional enteroids (able to generate crypt structures, Figure 3F, white
arrows) was observed when compound #5 was added 3 hours after
irradiating the intestinal enteroids in vitro (P = .0479, Figure 3G).
F IGURE 3 Compound #5 stimulates proliferation in crypt cells in the small intestines of irradiated mice. A-D, C3H mice were sham-irradiated
(A, B) or received 16 Gy of total body irradiation (C, D) and 24 hours later were administered Cremophor/DMSO (A, C) or a single dose of
compound #5 (5 mg/kg; B, D) subcutaneously. Twenty-four hours after administering compound #5 (48 hours after irradiation exposure), the
duodenums were removed, fixed, and thin cross-sections were stained for the proliferation marker Ki67 (A-D). The number of Ki67-pos cells
(brown stain; B, D) per region of interest present in at least five circumferences per mouse were counted. Scale bar: 100 μM. (b) and (d) are full
size images of the regions indicated in (B) and (D). E, A single treatment with compound #5 resulted in a significant increase in the number of
Ki67-pos cells after exposure to a lethal dose (16 Gy) of total body irradiation (P < .0001, two-tailed Student's t test) in the small intestines of
irradiated mice (E, light bars) but no significant change in the intestines of nonirradiated animals (E, dark bars). F, In order to test if compound #5
affected intestinal stem cells, small intestines of C3H mice were removed and crypts were isolated and cultured for propagating intestinal
enteroids in vitro. The three-dimensional in vitro enteroid cultures form crypt-like budding structures (white arrows) that recapitulate the in vivo
crypt structures contain the intestinal stem cell compartment, thus providing a method for testing the effect of different treatments on the
intestinal stem cells in vitro. Scale bar: 50 μM. G, Treatment of in vitro intestinal enteroids with a single dose of 3 Gy significantly decreases the
number of budding enteroids, indicating a significant loss or damage of intestinal stem cells. This radiation-induced intestinal stem cell loss was
mitigated by daily treatment with compound #5 (10 μM). G, Graphs represent the average percent budding enteroids per well ± SEM. *, P < .05;
**, P < .01; ****, P < .0001. H, In order to test if compound #5 can substitute for R-Spondin1, intestinal enteroids isolated from C3H mice were
propagated and placed in media made with or without the critical enteroid growth factor R-Spondin1 and/or compound #5 (10 μM). The cells
were sham-irradiated or treated with a single dose of 3 Gy and the compound #5 was replaced daily, after 6 days the budding enteroids were
counted. Compound #5 could not substitute for the lack of R-Spondin1 but had an additive effect on enteroid budding in the presence of
R-Spondin1
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Piperazines are known scaffolds used in the drug development of
agonists and antagonists of G-protein coupled receptors (GPCR) and
since leucine rich repeat containing G protein-coupled receptor
5 (Lgr5) belongs to the family of GPCRs, we next tested if compound
#5 could substitute for R-spondin1, the natural ligand of Lgr5. When
established intestinal enteroids were dissociated and plated into R-
Spondin1-free media and treated with R-Spondin1 and/or compound
#5, no secondary enteroid formation was observed in cultures treated
with only compound #5 (Figure 3H). Cultures continuously treated
with R-Spondin1 formed budding enteroids. Similar results were
obtained when the enteroids were irradiated with a single dose of
3 Gy but the combined treatment with R-Spondin1 and compound #5
significantly increased the number of budding enteroids. This
indicated that compound #5 has a different molecular target than R-
Spondin1, which sustains and amplifies Wnt signaling.
3.3 | Compound #5 induces an acute
immunological response in the small intestines
At this point in our study the molecular target for compound #5 was
unknown, which hindered further optimization of the drug. Therefore,
we decided to study acute gene expression changes in the murine
small intestines after a single dose of compound #5. Animals were
treated with s.c. injections of compound #5 or Cremophor/DMSO.
The small intestines were harvested 4 hours later, flushed with PBS
F IGURE 4 Compound #5 induces an immunological gene expression signature. Female, 12-week-old C3H mice were treated with
Cremophor/DMSO or compound #5. Four hours after treatment the small intestines were harvested and subjected to RNASeq analysis to
identify pathways engaged early after treatment with compound #5. Only 15 genes were differentially expressed. A, Volcano plot of genes up or
downregulated. B, Log2-fold change in expression of individual genes. C, qRT-PCR validation of six genes differentially expressed (*, P < .05 and
***, P < .001, Student's t test; D) gene set enrichment analysis of overlapping genes
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and total RNA was extracted from the proximal portion of the duode-
num. Surprisingly, RNASeq resulted in the differential expression of
only 15 genes in animals treated with compound #5 (Figure 4A,B).
The upregulation of six of these genes was confirmed using qRT-PCR
(Figure 4C) Gene set enrichment analysis computed overlaps with
immunological signatures (Figure 4D), which was in agreement with
our previous report of increased cellularity in Peyer's patches, the
immune system of the gut, after treatment with compound #5.21
3.4 | Effects of compound #5 on developmental
signaling pathways in the intestinal crypt
Since the increased number of regenerating crypts after treatment
with compound #5 pointed to increased numbers of ISCs we next
studied if pathways known to be involved in ISC renewal were acti-
vated in response to compound #5 treatment. Because ISCs are par-
ticularly dependent upon Wnt pathway activation and the Wnt
F IGURE 5 Compound #5 does not significantly induce Wnt, notch, or hippo signaling. A-D, Female, 12-week-old C3H mice were sham-
irradiated (A, B) or subjected to 16 Gy total body irradiation (C, D). Twenty-four hours later, the mice were treated with Cremophor/DMSO (A, C)
or compound #5 (5 mg/kg; B, D) subcutaneously. Twenty-four hours after compound #5 treatment (48 hours after irradiation), intestines were
removed, fixed, and thin cross-sections were stained for β-catenin. Compound #5 modestly increased β-catenin staining in vivo with minimal
induction of nuclear localization. Scale bar: 100 μM. (a)-(d) are full size images of the regions indicated in (A)-(D). E, Female, 12-week-old C3H
mice were subjected to 16 Gy total body irradiation. Twenty-four hours later, the mice were treated with Cremophor/DMSO or compound #5
(5 mg/kg) subcutaneously. Twenty-four hours after compound #5 treatment (48 hours after irradiation), intestines were removed, fixed, and thin
cross-sections were stained for Notch1-ICD, the active form of Notch1. Compound #5 did not increase Notch1-ICD staining in vivo, thus
excluding Notch1 as a target for compound #5. Scale bar: 100 μM. F, Small intestines of C3H mice were removed and crypts were isolated and
cultured for propagating intestinal enteroids in vitro. Enteroids were treated with DMSO or compound #5 (10 μM) for 24 hours. The enteroids
were removed from the matrix and attached to slides using a cytospin (Shandon Elliot, Tacoma, Washington). The slides were fixed,
permeabilized, and stained for YAP/TAZ and a nuclear counterstain. The slides were imaged using confocal microscopy. Compound #5 not affect
the nuclear localization of YAP/TAZ, suggesting that the Hippo signaling pathway was not affected by compound #5. Scale bar: 50 μM
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pathway drives many of the canonical stem cell markers of the small
intestine, we assessed whether compound #5 activated Wnt signaling
in vivo. Staining against β-catenin at 48 hours after irradiation and
24 hours after drug treatment revealed weak stabilization and nuclear
translocation of β-catenin (Figure 5A-D) thus, indicating that com-
pound #5 does not significantly activate the Wnt signaling pathway
directly or indirectly. Furthermore, this analysis was hindered by the
variation of β-catenin staining in each circumference and the known
gradual 10-fold decrease of Wnt signaling from the proximal to the
distal small intestines.22
Next, we tested if compound #5 activated Notch signaling, a sec-
ond pathway that is involved in the maintenance of the intestinal
crypt.23 Staining compound #5-treated section with an antibody
against Notch1-ICD, the intracellular domain of the cleaved, active
form of Notch1 showed variation of Notch activation in the individual
circumferences but no clear Notch activation pattern in response to
compound #5 (Figure 5E).
The Hippo pathway is also critical during crypt regeneration after
injury, including radiation injury.24 Hippo pathway components
YAP/TAZ are activated and localized to the nucleus during recovery
from radiation injury. We assayed for Hippo pathway activation using
in vitro enteroids treated for 24 hours with compound #5 or DMSO.
The enteroids were fixed, stained with antibodies against YAP/TAZ
and a nuclear counterstain (DAPI) and analyzed by confocal
microscopy. Compound #5 had no apparent effect on the nuclear
translocation of YAP/TAZ proteins in crypt-like structures (Figure 5F).
To further investigate potential mechanisms of action of com-
pound #5, we created a qPCR array of ISC genes and components of
major stem cell signaling pathways (Table S1). Gene expression analy-
sis of the proximal portions of the duodenums of mice treated with
compound #5 for 24 hours versus Cremophor/DMSO-treated animals
revealed a significant downregulation of Cysteine-rich angiogenic
inducer 61 (Cyr61), Axin related protein 2 (Axin2), connective tissue
growth factor (Ctgf ), SPARC realted modular calcium binding
2 (Smoc2), Octamer-binding transcription factor 4 (Oct4), Yap1, Dachs-
hund family transcription factor 1 (Dach1), Musashi RNA binding
prorein 1 (Msi1), and Hairy/enhancer of split related with YRPW motif
like protein (HeyL; Figure 6A), while only the expression level of the
hedgehog-driven gene Gli1 (GLI family zinc finger 1) was significantly
upregulated (Figure 6B).
In order to gain further insight into the mechanism by which com-
pound #5 targets the Hedgehog pathway, we overexpressed
Smoothened-mCherry (SMO-mCherry) in HK293 cells. When treated
with 5 nM boron-dipyrromethene (BODIPY)-cyclopamine (a green-
fluorescent form of the well-known Smoothened inhibitor
cyclopamine), SMO-mCherry and cyclopamine colocalized (Figure 7A).
Addition of compound #5 displaced BODIPY-cyclopamine from SMO-
mCherry in a concentration-dependent manner (Figure 7B). In order
F IGURE 6 Compound #5 induces
Gli1 expression. Female, 12-week-old
C3H mice were treated with Cremophor
or compound #5. Twenty-four hours after
drug treatment the small intestines and
the proximal portion of the duodenum
was harvested and subjected to qRT-PCR
analysis using a custom intestinal stem
cell PCR primer array. Treatment with
compound #5 significantly downregulated
the expression of Cyr61, Axin2, Ctgf,
Smoc2, Oct4, Yap1, Dach1, Msi1, and
HeyL (A) but led to an upregulation of
Gli1 (B; *, P < .05, Student's t test)
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F IGURE 7 Compound #5 binds to Smoothened and activates Gli signaling. A, HEK293 cells were transiently transfected with an expression
construct for mCherry-tagged Smoothened protein. Smoothened-mCherry overexpressing cells (red) were treated with BODIPY-cyclopamine
(green), fixed, counterstained with DAPI and imaged using confocal microscopy (×63 magnification, scale bar: 50 μM). The BODIPY signal
colocalized with the Smoothened protein. B, HEK293 cells, overexpressing Smoothened-mCherry were pretreated with BODIPY-cyclopamine
(green). Treatment with compound #5 led to a concentration-dependent replacement of cyclopamine from its binding site. Images show clusters
of HEK293 cells at ×4 magnification. Scale bar: 200 μM. C, Quantification of the replacement of BODIPY-cyclopamine by compound #5 in
mCherry-tagged Smoothened protein overexpressing HEK293 using flow cytometry determined an IC50 of 88 μM ± 3.7 μM for compound #5
(three biologically independent repeats). D, Compound #5 caused a concentration-dependent activation of a Gli signaling (*, P < .05 and **,
P < .01, Student's t test). E, Compound #5 significantly attenuated the inhibitory effect of the Smoothened inhibitor Vismodegib in a budding
enteroid assay. F, In silico docking results for compound #5 predicted binding to the transmembrane domain of Smoothened. G, LigPlot 2D
presentation of the interactions of compound #5 with the transmembrane domain of Smoothened
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to quantify this effect, we repeated the experiment and analyzed the
cells using flow cytometry, which determined an IC50 of 88 ± 3.7 μM
for compound #5 (Figure 7C). This indicated that compound #5 could
potentially occupy the same binding region as cyclopamine, which
binds to the transmembrane region of Smoothened.25 When Smooth-
ened is activated it translocates to the primary cilium where it pre-
vents proteasomal degradation of the zinc-finger transcription factor
Gli.26 To further confirm engagement of the Hedgehog pathway we
treated Gli1-Luc reporter cells, in which luciferase expression is under
control of a Gli binding element, with compound #5. This led to a
dose-dependent activation of the reporter construct, thus supporting
activation of the Hedgehog pathway by compound #5. Treatment of
the cells with recombinant murine sonic hedgehog (Shh), a known
Hedgehog agonist, activated the Gl1-responsive element to the same
order of magnitude as compound #5 and this activation was inhibited
by the Hedgehog antagonist Vismodegib (Figure 7D). In order to test
functionally if compound #5 binds to SMO, murine small intestinal
enteroids were treated with Vismodegib, another Hedgehog pathway
inhibitor. Addition of compound #5 attenuated the effects of Vis-
modegib on budding crypt formation in this model (Figure 7E).
Finally, we performed in silico docking studies, which predicted
binding of compound #5 to the transmembrane domain of Smooth-
ened with a hydrogen bond to Lys395 and a binding free energy of
−10.01 kCal/mol (Figure 7F,G).
4 | DISCUSSION
Nuclear accidents, terrorist attacks with dirty bombs, or deployed
nuclear weapons will potentially expose large numbers of the general
public and first responders to substantial doses of ionizing radiation.27
Even in developed countries, the resulting number of victims suffering
from ARS will outnumber the capacity of facilities able to provide high-
end supportive care or bone marrow transplants.28 Providing care for an
overwhelming number of people that would be exposed to radiation in
such a scenario would be further complicated by the necessity to deliver
treatment as early as possible after exposure. Yet, in a mass-casualty sce-
nario delivering a treatment within the first 24 hours after exposure
would be impossible for the majority of the victims.8-10 Therefore, cur-
rent approaches aiming at discovering effective radiation mitigators
focus on drugs that show efficacy when given 24 hours (or later) after
radiation exposure in order to be of use under such circumstances.6
Severe damage to the gut will be one of the life-threatening radi-
ation injuries that will require immediate attention.7 Within hours to
days after radiation exposure, the intestinal epithelium responds with
massive cell death, villi are lost and the barrier function of the intes-
tines is compromised. Left untreated, victims will succumb to massive
loss of fluids, bleeding, malabsorption, and sepsis.
Hypothetically, the intestine's response to radiation could be
modified in different ways. A first approach could be through facilitat-
ing the repair of DNA damage caused by radiation exposure and pre-
vention of apoptosis. However, in the small intestines, repair of
potentially lethal DNA damage after exposure to radiation is a process
that starts early after exposure and is mostly completed after
4 hours.3 Therefore, if a treatment aims at improving or promoting
DNA repair any successful intervention would have to be adminis-
tered in advance or at least rapidly after radiation exposure, which
would face the above-mentioned major logistic obstacles if a larger
number of people are exposed at the same time. Likewise, apoptosis
in the small intestines is a rapid process that peaks at 4 hours after
irradiation is completely initiated at 24 hours,29 thus excluding at least
the primary wave of apoptosis as a potential intervention point for
radiation mitigators. However, compounds aiming at preventing apo-
ptosis could still be useful in reducing secondary or tertiary waves of
programmed cell death in the intestines.
An alternative approach could be the expansion of the ISC pool
either from surviving ISCs by stimulation of symmetric divisions, recruit-
ment and interconversion of reserve stem cell populations, or dedifferen-
tiation of differentiating progeny into a stem cell state.30-32 Treatments
to achieve these goals would allow for a wider time window and would
most likely rely on activating pathways involved in ISC and TA cell pool
expansion and/or ISC and TA cell interconversion, a process thought to
be driven byWnt, Notch, Hippo, andHedgehog signaling.23
Here, we report that treatment with the radiation mitigator com-
pound #5 24 hours after exposure to a lethal dose of radiation led to
an increased proliferation of crypt cells 48 hours after irradiation
(Figure 3A-D), a significant increase in the number of regenerating
crypts at 96 hours after irradiation (Figure 3E) and a significant
increase in survival of the animals (Figure 1). The microcolony assay
for regenerating crypts used in our study is the gold standard for
assessing the number of surviving ISCs4 and thus, the increase in
numbers of regenerating crypts indicated that compound #5 indeed
affected the size of the ISC pool (Figure 1G). This was further
supported by the finding that compound #5 significantly increased
the number of budding enteroids in an in vitro intestinal enteroid
assay. In these three-dimensional intestinal enteroid (mini-guts) assays
the “budding” structures (Figure 3F,G) are believed to recapitulate the
in vivo crypt structures, which contain the ISC compartment within a
niche of other supporting cells.5
In search for the molecular mechanisms behind our in vitro and
in vivo observations we next performed RNASeq. Our results showed
that the expression levels of only a surprisingly small number of genes
were altered 4 hours after compound #5 treatment (Figure 4A). It has
to be noted that the whole proximal portion of the duodenum was
used for this experiment, which included not only crypts but also the
mucosa and submucosa portion of the intestines. This experimental
route was chosen to test for global effects of compound #5 on the
intestines and because the target cell population was not narrowed
down at this point. By design, this experiment did not have the
required signal-to-noise ratio that would allow for detection of gene
expression changes in only the small population of crypt cells and we
interpreted these results as an indicator for a small target cell popula-
tion for compound #5.
Consequently, we next explored the developmental pathways
that govern ISC renewal (Figure 5) as potential targets for compound
#5 and demonstrated that compound #5 activated the Hedgehog
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pathway, as the mRNA of the downstream target Gli1 was signifi-
cantly upregulated 24 hours after treatment of the animals with com-
pound #5 and reporter cells showed activation of a Gli1-responsive
element, comparable to activation by recombinant mShh (Figures 6B
and 7D). Competition experiments and in silico docking studies
supported direct binding of compound #5 to the transmembrane
domain of Smoothened (Figure 7). Smoothened is known to be
expressed in only a small population of pericryptal stromal cells,33
bone marrow-derived stromal cells34 and in follicular dendritic cells in
the germinal centers.35 In mouse models of inflammatory bowel dis-
ease Hedgehog signaling in stromal cells at the base of the crypt leads
to increased IL-10 production as a major anti-inflammatory mecha-
nism.33 This is in agreement with our observation that compound #5
not only mitigated the GI-ARS but also led to increased cellularity in
the germinal centers of Peyer's patches,21 prevented hematopoietic
ARS,12 increased the number of peripheral CD11b+Ly6C+Ly6G+ mye-
loid cells and stimulated IL-10 production.12 At this point it is unclear
if compound #5 acts on ICSs directly or indirectly. Compound #5
increased ICSs in vitro but early enteroid passages will most likely still
contain stromal components and is quite likely that compound #5 cre-
ates an anti-inflammatory environment permissive for ICS expansion
or interconversion. Future studies are warranted to determine the tar-
get cell population for Piperazines in the small intestines.
5 | CONCLUSION
We conclude that Piperazines are a novel class of Smoothened ago-
nists and that Smoothened is an attractive and druggable target to
mitigate the GI-ARS.
ACKNOWLEDGMENTS
F.P. was supported by a grant from the National Institute of Allergy
and Infectious Diseases (AI067769) and by grants from the National
Cancer Institute (CA211015, CA200234).
CONFLICT OF INTEREST
The authors declare no potential conflict of interest.
AUTHOR CONTRIBUTIONS
S.D.M., K.B., E.V.: collection and assembly of data acquisition, data
analysis and interpretation, manuscript writing, final approval of the
manuscript; P.M., F.C., L.H., C.A., M.S., S.D.M., G.R., M.E.: collection
and assembly of data acquisition, data analysis and interpretation, final
approval of the manuscript; F.P.: manuscript writing, conception and
design, financial support, final approval of the manuscript.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
ORCID
Frank Pajonk https://orcid.org/0000-0003-4067-9751
REFERENCES
1. Warren S, Bowers JZ. The acute radiation syndrome in man. Ann
Intern Med. 1950;32:207-216.
2. Weisdorf D, Chao N, Waselenko JK, et al. Acute radiation injury: con-
tingency planning for triage, supportive care, and transplantation. Biol
Blood Marrow Transplant. 2006;12:672-682.
3. Withers HR, Elkind MM. Radiosensitivity and fractionation response
of crypt cells of mouse jejunum. Radiat Res. 1969;38:598-613.
4. Withers HR, Elkind MM. Microcolony survival assay for cells of
mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat
Stud Phys Chem Med. 1970;17:261-267.
5. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-
villus structures in vitro without a mesenchymal niche. Nature. 2009;
459:262-265.
6. Brenner DJ, Chao NJ, Greenberger JS, et al. Are we ready for a radio-
logical terrorist attack yet? Report from the centers for medical coun-
termeasures against radiation network. Int J Radiat Oncol Biol Phys.
2015;92:504-505.
7. Williams JP, McBride WH. After the bomb drops: a new look at
radiation-induced multiple organ dysfunction syndrome (MODS). Int J
Radiat Biol. 2011;87:851-868.
8. Department of Homeland Security USA, Homeland Security Council.
National Planning Scenarios, version 20.2. 2009.
9. Davis LE, LaTourrette T, Mosher DE, Davis LM, Howell DR. Individual
Preparedness and Response to Chemical, Radiological, Nuclear, and Bio-
logical Terrorist Attacks. Santa Monica, CA: RAND Corporation; 2003.
10. Carter AB, May MM, Perry WJJF. The day after: action following a
nuclear blast in a U.S. city.Washington Q. 2007;30:19-32.
11. Kim K, Damoiseaux R, Norris AJ, et al. High throughput screening of
small molecule libraries for modifiers of radiation responses. Int J
Radiat Biol. 2011;87:839-845.
12. Micewicz ED, Kim K, Iwamoto KS, et al. 4-(Nitrophenylsulfonyl)piper-
azines mitigate radiation damage to multiple tissues. PLoS One. 2017;
12:e0181577.
13. Plett PA, Sampson CH, Chua HL, et al. Establishing a murine model of
the hematopoietic syndrome of the acute radiation syndrome. Health
Phys. 2012;103:343-355.
14. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide
expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-15550.
15. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive
genes involved in oxidative phosphorylation are coordinately down-
regulated in human diabetes. Nat Genet. 2003;34:267-273.
16. Sato T, Clevers H. Primary mouse small intestinal epithelial cell cul-
tures. Methods Mol Biol. 2013;945:319-328.
17. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and
AutoDockTools4: automated docking with selective receptor flexibil-
ity. J Comput Chem. 2009;30:2785-2791.
18. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visuali-
zation system for exploratory research and analysis. J Comput Chem.
2004;25:1605-1612.
19. O'Boyle NM, Banck M, James CA, et al. Open babel: an open chemical
toolbox. J Chem. 2011;3:33.
20. Mason KA, Withers HR, McBride WH, et al. Comparison of the gas-
trointestinal syndrome after total-body or total-abdominal irradiation.
Radiat Res. 1989;117:480-488.
21. Bhat K, Duhachek-Muggy S, Ramanathan R, et al.
1-(4-Nitrobenzenesulfonyl)-4-phenylpiperazine increases the number
of Peyer's patch-associated regenerating crypts in the small intestines
after radiation injury. Radiother Oncol. 2019;132:8-15.
118 DUHACHEK-MUGGY ET AL.
22. Davies PS, Dismuke AD, Powell AE, Carroll KH, Wong MH. Wnt-
reporter expression pattern in the mouse intestine during homeosta-
sis. BMC Gastroenterol. 2008;8:57.
23. de Sousa EMF, de Sauvage FJ. Cellular plasticity in intestinal homeo-
stasis and disease. Cell Stem Cell. 2019;24:54-64.
24. Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL. Yap-
dependent reprogramming of Lgr5(+) stem cells drives intestinal
regeneration and cancer. Nature. 2015;526:715-718.
25. Byrne EF, Luchetti G, Rohatgi R, et al. Multiple ligand binding sites
regulate the Hedgehog signal transducer Smoothened in vertebrates.
Curr Opin Cell Biol. 2018;51:81-88.
26. Briscoe J, TherondPP. Themechanisms ofHedgehog signalling and its roles
in development and disease.Nat RevMol Cell Biol. 2013;14:416-429.
27. Jordan BR. The Hiroshima/Nagasaki survivor studies: discrepancies
between results and general perception.Genetics. 2016;203:1505-1512.
28. Majhail NS, Mau LW, Chitphakdithai P, et al. National survey of hemato-
poietic cell transplantation center personnel, infrastructure, and models
of care delivery. Biol BloodMarrow Transplant. 2015;21:1308-1314.
29. Potten CS, Grant HK. The relationship between ionizing radiation-
induced apoptosis and stem cells in the small and large intestine. Br J
Cancer. 1998;78:993-1003.
30. Yousefi M, Li L, Lengner CJ. Hierarchy and plasticity in the intestinal
stem cell compartment. Trends Cell Biol. 2017;27:753-764.
31. Schmitt M, Schewe M, Sacchetti A, et al. Paneth cells respond to
inflammation and contribute to tissue regeneration by acquiring
stem-like features through SCF/c-kit signaling. Cell Rep. 2018;24:
2312.e2317-2328.e2317.
32. Beumer J, Clevers H. Regulation and plasticity of intestinal stem cells dur-
ing homeostasis and regeneration.Development. 2016;143:3639-3649.
33. Lee JJ, Rothenberg ME, Seeley ES, et al. Control of inflammation by
stromal Hedgehog pathway activation restrains colitis. Proc Natl Acad
Sci USA. 2016;113:E7545-E7553.
34. Shi S, Sun J, Meng Q, et al. Sonic hedgehog promotes endothelial dif-
ferentiation of bone marrow mesenchymal stem cells via VEGF-D.
J Thorac Dis. 2018;10:5476-5488.
35. Sacedon R, Diez B, Nunez V, et al. Sonic hedgehog is produced by fol-
licular dendritic cells and protects germinal center B cells from apo-
ptosis. J Immunol. 2005;174:1456-1461.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section.
How to cite this article: Duhachek-Muggy S, Bhat K,
Medina P, et al. Radiation mitigation of the intestinal acute
radiation injury in mice by 1-[(4-nitrophenyl)sulfonyl]-4-
phenylpiperazine. STEM CELLS Transl Med. 2020;9:106–119.
https://doi.org/10.1002/sctm.19-0136
RADIATION MITIGATION OF THE INTESTINAL ACUTE RADIATION INJURY IN MICE 119
